SCLP — Scancell Holdings Income Statement
0.000.00%
- £101.18m
- £100.56m
- £4.71m
Annual income statement for Scancell Holdings, fiscal year end - April 30th, GBP millions except per share, conversion factor applied.
2021 April 30th | R2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 5.27 | 0 | 4.71 |
Cost of Revenue | |||||
Gross Profit | — | — | 4.75 | 0 | 4.47 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.83 | 20.5 | 17.2 | 18.3 | 17.9 |
Operating Profit | -8.83 | -20.5 | -11.9 | -18.3 | -13.2 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -16.8 | -6.27 | -14.3 | -9.12 | -15.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15.5 | -4.57 | -11.9 | -5.86 | -12.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -15.5 | -4.57 | -11.9 | -5.86 | -12.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.5 | -4.57 | -11.9 | -5.86 | -12.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.024 | -0.001 | -0.015 | -0.007 | -0.014 |